| Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (NCT07264075) | Groupe Oncologie Radiotherapie Tete et Cou | 2026-05-05 |
| Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma (NCT07529873) | Groupe Oncologie Radiotherapie Tete et Cou | 2026-05-01 |
| Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck (NCT06959108) | Groupe Oncologie Radiotherapie Tete et Cou | 2025-10-13 |
| Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N (NCT06640725) | Groupe Oncologie Radiotherapie Tete et Cou | 2025-01-02 |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (NCT05930938) | Groupe Oncologie Radiotherapie Tete et Cou | 2023-12-12 |
| Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (NCT05930951) | Groupe Oncologie Radiotherapie Tete et Cou | 2023-11-29 |
| Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma (NCT04356170) | Groupe Oncologie Radiotherapie Tete et Cou | 2021-02-04 |
| Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (NCT03726775) | Groupe Oncologie Radiotherapie Tete et Cou | 2019-07-17 |
| A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NCT03576417) | Groupe Oncologie Radiotherapie Tete et Cou | 2018-10-10 |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (NCT02999087) | Groupe Oncologie Radiotherapie Tete et Cou | 2017-09-14 |
| Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (NCT02998385) | Groupe Oncologie Radiotherapie Tete et Cou | 2017-01-20 |
| Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (NCT02707588) | Groupe Oncologie Radiotherapie Tete et Cou | 2016-05-18 |
| Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (NCT03330249) | Groupe Oncologie Radiotherapie Tete et Cou | 2015-12-03 |
| Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (NCT03070366) | Groupe Oncologie Radiotherapie Tete et Cou | 2015-09-21 |
| Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT (NCT03340896) | Groupe Oncologie Radiotherapie Tete et Cou | 2015-06-25 |
| Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (NCT02268695) | Groupe Oncologie Radiotherapie Tete et Cou | 2014-10-10 |
| Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (NCT02216617) | Groupe Oncologie Radiotherapie Tete et Cou | 2014-08-06 |
| Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC (NCT01864850) | Groupe Oncologie Radiotherapie Tete et Cou | 2013-10-18 |
| Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (NCT01864772) | Groupe Oncologie Radiotherapie Tete et Cou | 2013-09-01 |
| Reirradiation and Erbitux in the HNSCC (NCT01237483) | Groupe Oncologie Radiotherapie Tete et Cou | 2010-10-01 |
| Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (NCT01228565) | Groupe Oncologie Radiotherapie Tete et Cou | 2010-08-01 |
| Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol (NCT01268878) | Groupe Oncologie Radiotherapie Tete et Cou | 2010-06-01 |
| Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01289522) | Groupe Oncologie Radiotherapie Tete et Cou | 2009-09-01 |
| Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (NCT01233843) | Groupe Oncologie Radiotherapie Tete et Cou | 2009-05-18 |
| Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (NCT00828386) | Groupe Oncologie Radiotherapie Tete et Cou | 2009-01-01 |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (NCT00609284) | Groupe Oncologie Radiotherapie Tete et Cou | 2008-02-15 |
| Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation (NCT00169247) | Groupe Oncologie Radiotherapie Tete et Cou | 2005-10-01 |
| IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC (NCT00158678) | Groupe Oncologie Radiotherapie Tete et Cou | 2005-09-27 |
| Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas (NCT00169221) | Groupe Oncologie Radiotherapie Tete et Cou | 2005-09-01 |
| Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma (NCT00169182) | Groupe Oncologie Radiotherapie Tete et Cou | 2001-12-15 |
| Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas (NCT00158691) | Groupe Oncologie Radiotherapie Tete et Cou | 2001-03-01 |
| Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC (NCT00158652) | Groupe Oncologie Radiotherapie Tete et Cou | 2000-03-01 |